With companion diagnostics, using Next-Generation Sequencing (NGS) technologies, Biologix Laboratories decodes the molecular drivers of cancer, enabling truly personalized care, and translates complex genomic data into actionable clinical insights that support accurate diagnosis, therapy selection, and disease monitoring.
Genetic cancer testing refers to advanced medical tests used to identify the most effective treatment for each cancer patient. By detecting specific biomarkers, such as genetic mutations, protein expressions, and molecular alterations, these tests reveal how a patient’s tumor is likely to respond to particular therapies. This allows clinicians to move beyond trial-and-error and select treatments that are targeted, precise, and more effective.
Tests Offered
Comprehensive 40-gene solid tumor panel with MSI detection, designed to identify SNVs, indels, fusions, and copy number alterations to guide precision oncology in colorectal, lung, bladder, and gastric cancers.
Advanced BRCA1 and BRCA2 sequencing panel detecting somatic and germline variants, including large rearrangements, to support targeted therapy decisions in breast, ovarian, and prostate cancers.
Comprehensive homologous recombination repair (HRR) gene panel analyzing 32 genes to detect actionable mutations and large rearrangements associated with breast, ovarian, and prostate cancers.
Integrated HRR gene mutation and genomic scar score (GSS) analysis to identify homologous recombination deficiency (HRD), enabling optimized treatment strategies for breast, ovarian, and prostate cancer patients.
Focused 10-gene panel detecting SNVs, indels, fusions, and CNVs in key oncogenic drivers (EGFR, ALK, ROS1, KRAS, NRAS, BRAF, HER2, MET, RET, PIK3CA) for lung and colorectal cancers. Optimized for both FFPE tissue and cfDNA with ultra-deep sequencing ≥10,000X.
Broad-spectrum 128-gene panel with MSI detection covering SNVs, InDels, fusions, CNVs, and SNPs (19 polymorphisms) for comprehensive genomic profiling. Compatible with both tissue and liquid biopsy samples across multiple cancer types including lung, colorectal, breast, gastric, thyroid, and urothelial cancers.
Advanced liquid biopsy panel analyzing 152 genes and MSI from plasma ctDNA to detect SNVs, InDels, fusions, CNVs, and SNPs. Ideal for patients with unknown cancer origin or when tissue biopsy is not feasible, supporting lung, colorectal, prostate, cervical, gastric, thyroid, and other solid tumors.
Comprehensive 195 pan-solid-tumor gene panel with integrated DNA and RNA analysis detecting SNVs, InDels, CNVs, HD, MSI, fusions, and MET exon 14 skipping. Designed for FFPE tumor tissue to provide complete genomic profiling across all major cancer types including lung, colorectal, breast, ovarian, prostate, glioma, and more.
Targeted 10-gene panel designed for comprehensive molecular classification and hereditary risk assessment, enabling detection of SNVs, InDels, CNVs, and MSI status from blood or FFPE tissue to support precision oncology, immunotherapy selection, and risk stratification.
Comprehensive 150-gene hereditary cancer panel detecting SNVs, InDels, and large rearrangements to identify major inherited cancer syndromes, enabling accurate risk assessment, personalized surveillance, and preventive care strategies in a single integrated workflow.
High-sensitivity hotspot panel analyzing key breast cancer genes with low variant allele frequency detection, supporting actionable mutation identification, targeted therapy decisions, and advanced translational research using both liquid biopsy and tissue samples.
Frequently asked questions
FAQs on Cancer Genetics Testing at Biologix Laboratories
Companion diagnostics (Cancer genetic testing) are specialized tests that help match patients with the most effective treatments based on their unique biomarkers.
CDx ensures that treatments are personalized, improving effectiveness, reducing side effects, and avoiding unnecessary medications.
We offer genetic testing for breast, lung, colorectal, prostate, and cervical cancers, among others.
Our tests are performed in a modern, high-quality laboratory using advanced technology to ensure precise and reliable results.
Turnaround time varies, but most results are available within 7–15 days, depending on the test type.
Patients diagnosed with certain cancers, those considering targeted therapy, or individuals with a family history of cancer can benefit from Cancer Genetic testing.
You can visit our lab or get a referral from your doctor, or contact us for more details on how to access our services.
Yes! We partner with AstraZeneca to provide free EGFR 29 mutation testing for eligible lung cancer patients with adenocarcinoma.
Our testing facility is in Anthony Village, Lagos, Nigeria, and we serve patients, hospitals, and clinics nationwide.
For inquiries, pricing, or test availability, kindly call or click on Resource link at the side.